X
Xiaoqing Liu
Researcher at Academy of Military Medical Sciences
Publications - 86
Citations - 9631
Xiaoqing Liu is an academic researcher from Academy of Military Medical Sciences. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 23, co-authored 78 publications receiving 7596 citations. Previous affiliations of Xiaoqing Liu include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok,Yi-Long Wu,Iveta Kudaba,Dariusz M. Kowalski,Byoung Chul Cho,Hande Turna,Gilberto de Castro,Vichien Srimuninnimit,Konstantin Laktionov,Igor Bondarenko,Igor Bondarenko,Kaoru Kubota,Gregory M. Lubiniecki,Jin Zhang,Debra Kush,Gilberto Lopes,Gonzalo Gomez Aubin,Luis Enrique Fein,Diego Kaen,Ruben Dario Kowalyszyn,Guillermo Lerzo,Gaston Martinengo,Matias Molina,Eduardo Richardet,Pablo Picon,Mirta Varela,J. J. Zarba,Sergio J Azevedo,Carlos H. Barrios,Carlos Beato,Carlos Alexandre Sydow Cerny,Pedro Rafael Martins De Marchi,Gustavo Fernandes,Fabio Franke,Helano C. Freitas,Gustavo Girotto,Valeria Lopes,Lucas Vieira dos Santos,Marcos Andre Costa,Andrea Kazumi Shimada,Oren Smaletz,Joao Paulo Holanda Soares,Ana Paula Victorino,Carlos Ferreira,Marchela Koleva,Krassimir Koynov,Rumyana Micheva,Tsvetan Deliverski,Zhasmina Milanova,Boyan Doganov,Susanna Cheng,Flavia De Angelis,Giovanna Speranza,Rosalyn A. Juergens,Doran Ksienski,David Fenton,Osvaldo Rudy Aren,Christian Caglevic,Hector Galindo,Felipe Rey,Jianhua Chang,Gongyan Chen,Xi Chen,Xuenong Ouyang,Ying Cheng,Zhenyu Ding,Mei Hou,Yun Fan,Jifeng Feng,Jianxing He,Yong He,Yi Hu,Wei Li,Xiaoqing Liu,Zhe Liu,Shun Lu,Shukui Qin,Qiyou Tang,Bu-Hai Wang,Kai Wang,Li Zhang,Xin Zhang,Jun Zhao,Jie Wang,Caicun Zhou,Jianying Zhou,Qing Zhou,Andrés F. Cardona,Ricardo Duarte,Luis Gomez Wolff,Angela Zambrano,Marcela Vallejo,Libor Havel,Vitezslav Kolek,Petr Kolman,Leona Koubkova,Lubos Petruzelka,Patrice Popelkova,Jaromir Roubec,Jaroslav Vanasek,Tomas Vlasek,Jana Jaal,Gerli Kuusk,Oscar Avendano,Hugo Castro,Karla Lopez,Mario Sandoval,Chung Man James Ho,Sing Hung Lo,Ibolya Laczó,Bela Piko,Gyula Ostoros,Keisuke Aoe,Yasuhito Fujisaka,Tomonori Hirashima,Atsushi Horiike,Yukio Hosomi,Katsuyuki Hotta,Masao Ichiki,Fumio Imamura,Yasuo Iwamoto,Kazuo Kasahara,Nobuyuki Katakami,Terufumi Kato,Shuji Murakami,Tomoya Kawaguchi,Kazuma Kishi,Takayasu Kurata,Yoshitaro Torii,Yasuharu Nakahara,Takashi Nishimura,Tatsuo Ohira,Hideo Saka,Toshiyuki Sawa,Nobuhiko Seki,Shunichi Sugawara,Kazuhisa Takahashi,Nagio Takigawa,Hiroshi Tanaka,Kazuhiko Yamada,Takuma Yokoyama,Toshihide Yokoyama,Hiroshige Yoshioka,Gunta Purkalne,Zinaida Stara,Alvydas Cesas,Saulius Cicenas,Marius Zemaitis,Soon Hin How,Chong-Kin Liam,Choo Khoon Ong,Lye Mun Tho,Oscar Arrieta Rodriguez,Carlos Hernandez Hernandez,Luis Mas,Luis Vera,Jorge Salas,Hermes Tejada,Regina Edusma-Dy,Christina Galvez,Guia Ladrera,Jerry Tan Chun Bing,Jacek Jassem,Ewa Kalinka-Warzocha,Boguslawa Karaszewska,Andrzej Kazarnowicz,Krzysztof Lesniewski Kmak,Rodryg Ramlau,António Araújo,Fernando Barata,Nuno Gil,Venceslau Hespanhol,A. Alexandru,Mircea Dediu,Nelly Cherciu,Daniel Ciurescu,Doina Ganea,Lucian Miron,Daniela Sirbu,Maria Turdean,Sergey Emelyanov,Nina Karaseva,Lyudmila Kuzina,Sergey Lazarev,Igor Dmitrievich Lifirenko,Larisa Bolotina,Oleg Lipatov,Elena Ovchinnikova,Marina Matrosova,Anna Alyasova,Artem Poltoratsky,Pavel Taranov,Oleg Zarubenkov,Graham Cohen,Lydia Dreosti,Freddy Seolwane,Jacqueline Hall,Gregory Hart,Christa Jordaan,Sayeuri Buddu,Michiel Botha,Gregory Landers,Bernardo Rappaport,Paul Ruff,Lucinda Shepherd,Waldemar Szpak,Myung-Ju Ahn,Joo Hang Kim,Per Bergstrom,Ronny Ohman,Hakan Griph,Daniel Betticher,Adrian F. Ochsenbein,Alfred Zippelius,Gee Chen Chan,Chao Hua Chiu,Te Chun Hsia,Wu Chou Su,Chih-Hsin Yang,Touch Ativitavas,Pongwut Danchaivijitr,Kasan Seetalarom,Aumkhae Sookprasert,Virote Sriuranpong,Ozden Altundag,Filiz Cay Senler,Mustafa Erman,Tuncay Göksel,Erdem Göker,Ozgur Ozyilkan,Mesut Seker,Mahmut Gumus,Fulden Yumuk,Grigory Adamchuk,Oleksandr Ivashchuk,Olga Ponomarova,Andrii Rusyn,Sergii Shevnya,Yaroslav Shparyk,Ivan Sinielnikov,Orest Andrusenko,Dmytro Trukhyn,Grygoriy Ursol,Ihor Vynnychenko,Tien Quang Nguyen,Xuan Dung Pham +245 more
TL;DR: Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations, and the benefit-to-risk profile suggests that first-line pembrology monotherapy can be extended as first line therapy for locally advanced or metastatic non-small-cell lung cancer patients with sensitising EGFR or ALK translocation.
Journal ArticleDOI
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Yi-Long Wu,Caicun Zhou,Chong-Kin Liam,G. Wu,Xiaoqing Liu,Z. Zhong,S. Lu,Y. Cheng,B. Han,Lei Chen,C. Huang,S. Qin,Y. Zhu,H. Pan,H. Liang,E. Li,G. Jiang,Soon Hin How,M.C.L. Fernando,Y. Zhang,F. Xia,Y.-X. Zuo +21 more
TL;DR: It is demonstrated that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965).
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
Yuankai Shi,Li Zhang,Xiaoqing Liu,Caicun Zhou,Shucai Zhang,Dong Wang,Qiang Li,Shukui Qin,Chunhong Hu,Yiping Zhang,Jianhua Chen,Ying Cheng,Jifeng Feng,Helong Zhang,Yong Song,Yi-Long Wu,Nong Xu,Jianying Zhou,Rongcheng Luo,Chunxue Bai,Ye-ning Jin,Wenchao Liu,Zhaohui Wei,Fenlai Tan,Yinxiang Wang,Lieming Ding,Hong Dai,Shunchang Jiao,Jie Wang,Li Liang,Weimin Zhang,Yan Sun +31 more
TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.